Oscar Health Q3 Profit and Guidance Raise Challenge Bear Thesis, But Risk Adjustment Volatility Remains

What happened

Oscar Health reported a profitable third quarter and raised its full-year operating earnings outlook for the third time, citing higher membership, premium rate increases, and a $250 million benefit from updated risk-adjustment data. This development contrasts with the prior DeepValue master report, which had rated the stock a potential sell due to concerns over a growing risk-adjustment payable and potential membership declines following the expiration of enhanced premium tax credits. The risk-adjustment benefit suggests that Oscar's relative risk score performance may be improving, potentially easing the balance-sheet pressure that had been a key bear thesis driver. However, the benefit appears to be a one-time update rather than a structural change, and the company's own guidance still implies a significant rise in the medical loss ratio from the unusually low Q1 level. Overall, the Q3 results reduce the immediate downside risk but do not eliminate the fundamental challenges of MLR normalization and ACA policy uncertainty.

Implication

The Q3 profitability and guidance raise indicate that Oscar is executing better than the bear case anticipated, with risk-adjustment moving favorably; this supports a higher probability for the base or bull scenarios. However, the $250 million risk-adjustment benefit is a reported update and may reflect timing or revised estimates rather than a structural improvement in risk score capture, so it should be scrutinized for sustainability. The prior report's concern about membership declines after enhanced APTC expiration remains valid for the 2027 enrollment cycle, meaning revenue growth could decelerate in the coming quarters. Management's own guidance still calls for MLR normalization to the low 80s, so the unusually low Q1 MLR of 70.5% is unlikely to repeat, and any reversion could pressure earnings. Therefore, while the bear case probability should be reduced, the stock is likely fairly valued near $20-22, and a disciplined approach would trim above $27 and consider adding only near $16-18 if evidence of durable operational improvement emerges.

Thesis delta

The Q3 report challenges the previous 'POTENTIAL SELL' thesis by showing a third consecutive guidance raise and a risk-adjustment benefit rather than a drag. The evidence of higher membership and premium rates mitigates the scale-leverage risk from eAPTC expiration, and the risk-adjustment update suggests the company may be closing the gap on relative risk scores. However, the benefit is likely a one-time adjustment, and the underlying MLR normalization and policy uncertainty remain; thus, the thesis shifts from 'potential sell' to 'neutral' with a need for more quarters of consistent operational outperformance before turning constructive.